Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTRO: Guselkumab induction therapy for moderately to severely active ulcerative colitis
jRCT2031220426Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in autoimmune colitis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical remission at Week 12 (modified Mayo score). Started Jan 2023; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031220426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220426.